Skip to content
6-K

Foreign Interim / Material

NIGHTSTAR THERAPEUTICS PLC

0001564590-18-029925

← back to feed
Filed
Nov 20, 2018 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Capex Q3 2018 · Sep 30, 2018 $387K
Capex Q3 2018 · Sep 30, 2017 $107K
Operating Cash Flow Q3 2018 · Sep 30, 2018 −$28.66M
Operating Cash Flow Q3 2018 · Sep 30, 2017 −$15.41M
Cash And Equivalents Q3 2018 · Sep 30, 2018 $45.97M
Cash And Equivalents Q3 2018 · Dec 31, 2017 $129.4M
Stockholders Equity Q3 2018 · Sep 30, 2018 $99.68M
Stockholders Equity Q3 2018 · Dec 31, 2017 $125.81M
Current Liabilities Q3 2018 · Sep 30, 2018 $14.76M
Current Liabilities Q3 2018 · Dec 31, 2017 $9.39M
Total Liabilities Q3 2018 · Sep 30, 2018 $14.76M
Total Liabilities Q3 2018 · Dec 31, 2017 $9.39M
Current Assets Q3 2018 · Sep 30, 2018 $113.28M
Current Assets Q3 2018 · Dec 31, 2017 $134.84M
Total Assets Q3 2018 · Sep 30, 2018 $114.44M
Total Assets Q3 2018 · Dec 31, 2017 $135.2M
Sga Expense Q3 2018 · Sep 30, 2018 $3.02M
Sga Expense Q3 2018 · Sep 30, 2018 $9.12M
Sga Expense Q3 2018 · Sep 30, 2017 $2.03M
Sga Expense Q3 2018 · Sep 30, 2017 $3.43M
Rd Expense Q3 2018 · Sep 30, 2018 $7.85M
Rd Expense Q3 2018 · Sep 30, 2018 $21.96M
Rd Expense Q3 2018 · Sep 30, 2017 $3.98M
Rd Expense Q3 2018 · Sep 30, 2017 $10.28M
Net Income Q3 2018 · Sep 30, 2018 −$6.02M
Net Income Q3 2018 · Sep 30, 2018 −$28.48M
Net Income Q3 2018 · Sep 30, 2017 −$8.21M
Net Income Q3 2018 · Sep 30, 2017 −$15.9M